Publication
Initial Use of Endothelial Progenitor Cells Capturing Stents in Paediatric Congenital Heart Disease
| dc.contributor.author | Cabanelas, N | |
| dc.contributor.author | Martins, JD | |
| dc.contributor.author | Pinto, MF | |
| dc.date.accessioned | 2017-10-24T14:28:12Z | |
| dc.date.available | 2017-10-24T14:28:12Z | |
| dc.date.issued | 2014-10 | |
| dc.description.abstract | INTRODUCTION: Stenosis, mediated by neointimal hyperplasia and thrombosis, is a major limiting factor in successful stent implantation. The introduction of a stent, coated in its endoluminal surface by antihuman CD34 antibodies with endothelial progenitor cell-capturing properties, opens the possibility of promoting a rapid and normal functioning coverage by endothelium and thus avoids both an excessive cell proliferation within stent and the need for long-term dual antiplatelet therapy. These stents, developed for adult coronary artery disease, have not yet been implanted in children or in those with congenital heart disease. OBJECTIVE AND METHODS: In this paper, we describe the implantation of Genous® stents in three children with cyanotic congenital heart disease and obstructed systemic-to-pulmonary shunts. We describe the use of this stent and address its potential feasibility in paediatric congenital heart disease. RESULTS: To maintain the patency of two modified Blalock-Taussig shunts and one ductus arteriosus, four Genous® stents were implanted in three infants with cyanotic heart disease. All procedures were immediately successful, with resolution of stenosis and improvement in transcutaneous oxygen saturation from 66% ± 3.6% to 92% ± 2.6%. In the follow-up, one stent had no occlusion; however, the remaining two had partial occlusion after 5 and 5.5 months, which were successfully managed with balloon dilatation preceding elective definitive surgical correction. CONCLUSION: In our preliminary experience, we demonstrated that Genous® stent implantation was feasible in infants with complex congenital heart disease. Additional studies with larger samples and longer follow-up are required to confirm the potential benefits of this technology in this clinical setting. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Cardiol Young. 2014 Oct;24(5):900-4 | pt_PT |
| dc.identifier.doi | 10.1017/S1047951113001376 | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10400.17/2768 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Cambridge University Press | pt_PT |
| dc.subject | Antibodies | pt_PT |
| dc.subject | Antigens, CD34 | pt_PT |
| dc.subject | Blalock-Taussig Procedure | pt_PT |
| dc.subject | Cardiac Catheterization | pt_PT |
| dc.subject | Endothelial Progenitor Cells | pt_PT |
| dc.subject | Feasibility Studies | pt_PT |
| dc.subject | Female | pt_PT |
| dc.subject | Heart Defects, Congenital | pt_PT |
| dc.subject | Humans | pt_PT |
| dc.subject | Infant, Newborn | pt_PT |
| dc.subject | Male | pt_PT |
| dc.subject | Prosthesis Design | pt_PT |
| dc.subject | Thrombosis | pt_PT |
| dc.subject | Treatment Outcome | pt_PT |
| dc.subject | Drug-Eluting Stents | pt_PT |
| dc.subject | Embolic Protection Devices | pt_PT |
| dc.subject | HSM CAR PED | pt_PT |
| dc.title | Initial Use of Endothelial Progenitor Cells Capturing Stents in Paediatric Congenital Heart Disease | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 904 | pt_PT |
| oaire.citation.issue | 5 | pt_PT |
| oaire.citation.startPage | 900 | pt_PT |
| oaire.citation.title | Cardiology in the Young | pt_PT |
| oaire.citation.volume | 24 | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |